Quesada, Odayme
Scantlebury, Dawn C.
Briller, Joan E.
Michos, Erin D.
Aggarwal, Niti R.
Article History
Accepted: 14 November 2022
First Online: 6 February 2023
Compliance with Ethical Standards
:
: Dr. Quesada is supported by the NIH K23-HL151867. Dr. Michos is supported by the Amato Fund in Women’s Cardiovascular Health at Johns Hopkins University. Dr. Michos reports Advisory Boards with Amarin, AstraZenca, Bayer, Boehringer Ingelheim, Esperion, Novartis, Novo Nordisk, and Pfizer. Dr. Briller is an unpaid consultant for the Illinois Maternal Mortality Committee and is on the Steering committee for the REBIRTH trial of bromocriptine in Peripartum Cardiomyopathy (NCT05180773).
: This article does not contain any studies with human or animal subjects performed by any of the authors.